Gyre Therapeutics GYRE
NASDAQ GYRE
$7.08 -0.25 (-3.41%)
As of: Oct 1, 2026 · 1:57 PM EDT

Gyre Therapeutics (GYRE) EV to EBITDA (2011 - 2025)

Updated

Gyre Therapeutics' EV to EBITDA was 60.39 in Q4 2025, up 1.6% from 59.43 a year earlier but down 8.4% from the prior quarter.

Analysis

Gyre Therapeutics (GYRE) EV to EBITDA (2011 - 2025) Analysis & Trends

For FY2025, EV to EBITDA at Gyre Therapeutics came in at 41.32, down 30.5% from FY2024.

  • In earlier years, EV to EBITDA was 59.43 in FY2024 and 2.72 in FY2022.
  • Quarterly EV to EBITDA has moved between -0.63 (Q3 2022) and 88.14 (Q2 2025) over five years.
  • Per Business Quant data, GYRE's EV to EBITDA in the three quarters before Q4 2025 was 65.95 (Q3 2025), 88.14 (Q2 2025) and 56.74 (Q1 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Gyre Therapeutics 777.23 Mn 579.94 Mn 26.90 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 60.39
Sep 30, 2025 65.95
Jun 30, 2025 88.14
Mar 31, 2025 56.74
Dec 31, 2024 59.43
Sep 30, 2023 4.46
Mar 31, 2023 -0.01
Dec 31, 2022 2.72
Sep 30, 2022 -0.63
Sep 30, 2012 49.77
Sep 30, 2011 200.18
Jun 30, 2011 35.90
API Access

Gyre Therapeutics EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=GYRE&period=max&api_key=YOUR_API_KEY